Standout Papers
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib (2005)
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2005)
Immediate Impact
1 by Nobel laureates 20 from Science/Nature 91 standout
Citing Papers
Toward personalized treatment approaches for non-small-cell lung cancer
2021 Standout
Harnessing innate immunity in cancer therapy
2019 StandoutNature
Works of David A. Ramies being referenced
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
2005 Standout
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2005 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| David A. Ramies | 2817 | 2647 | 314 | 1195 | 37 | 3.8k | |
| Anh T. Le | 2249 | 2068 | 477 | 1344 | 56 | 3.4k | |
| Venice Archer | 3528 | 3498 | 209 | 901 | 16 | 4.6k | |
| Lorinda Simms | 3545 | 3449 | 262 | 983 | 37 | 5.0k | |
| Andrew Weickhardt | 2274 | 2229 | 378 | 947 | 107 | 3.2k | |
| Lara Felicioni | 2190 | 1876 | 369 | 1592 | 37 | 3.7k | |
| Mark S. Huberman | 3221 | 2978 | 353 | 1195 | 80 | 4.4k | |
| Anthony M. D’Amelio | 1534 | 1372 | 454 | 1396 | 37 | 2.8k | |
| Giovanna Finocchiaro | 1594 | 1579 | 326 | 877 | 67 | 2.7k | |
| Dae Ho Lee | 2910 | 2343 | 182 | 926 | 92 | 3.3k | |
| Davey B. Daniel | 2023 | 2170 | 233 | 524 | 80 | 3.2k |
All Works
Loading papers...